Serum angiotensin converting enzyme (ACE) activity in patients with chronic renal failure (CRF) on regular hemodialysis (HD) was measured. The enzyme activity of these patients was significantly higher than that of an age-matched control group. Additionally, we found that an elevated activity was observed in patients who had a longer history of HD. The enzyme activity in patients with CRF caused by diabetic nephropathy was higher than that in patients with CRF caused by chronic glomerulonephritis, though this difference was not significant. We conclude that diffuse vascular damage might be the cause of the increased ACE activity seen in CRF.
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bronchial asthma, bronchitis, and lung carcinoma.7) Lieberman and Sastre have shown that diffuse vascular damage in diabetes mellitus could release the enzyme into the blood. To examine whether such lesions exist in patients with chronic renal failure, we measured their serum ACE (S-ACE) activity . less than 3 years (p<0.001, Table IV ). There were no significant differences in the distribution of underlying diseases in the 2 groups. On the whole, there was significant direct correlation between the duration of HD and the level of enzyme activity (r=0.362, p<0.006, Fig. 1 ). There was no significant relationship between mean blood pressure and the level of enzyme activity (r=0.187).
MATERIALS
Changes in blood pressure before and after HD did not result in any alteration of the level of enzyme activity.
DISCUSSION
According to Ueda et al, an elevated level of ACE activity is frequently observed in the serum and granulomatous lymph nodes of patients with sarcoidosis.2)-4) Schweisfurth et al stated that in granulomatous diseases such as sarcoidosis and leprosy, elevation of the enzyme was said to be produced by the monocyte-derived cells comprising the granulomas. They also pointed out that S-ACE activity in patients with hepatic cirrhosis was significantly elevated as compared with healthy controls. These authors speculated that high S-ACE activity might originate primarily from an altered pulmonary circulation and indicated a higher convertion rate of angiotensin I during passage through the lung.8)
Patel et al demonstrated that S-ACE activity was increased in patients with CRF who underwent long term hemodialysis.9) In our present study, the enzyme activity in these patients was also significantly higher than in the control group. Patel speculated that the increased S-ACE activity might be caused by an increased pulmonary vascular area in patients with this disease. However, we postulate another mechanism for the increase of the enzyme activity in these patients.
It is generally accepted that ACE is widely distributed in the vascular endothelium of every organ, and that vascular endothelial cells are the major site of synthesis of ACE.8),10),11) Lieberman et al have shown that patients with diabetes mellitus have persistent or temporary elevation of S-ACE, and that elevation of the enzyme activity in diabetic patients is associated significantly with diabetic retinopathy.7) They speculated that diffuse vascular damage, including microangiopathy, in their cases might release the enzyme into the blood. In our study, although not significant, the enzyme activity in patients with CRF caused by diabetic nephropathy was higher than that in patients with chronic glomerulonephritis.
In addition, we found that elevated enzyme activity was observed in patients who had been undergoing HD for a longer duration. As to the relationship between CRF and vascular damage, Linder et al12) and Lazarus et al13) reported the occurrence of accelerated atherosclerosis in patients undergoing prolonged maintenance HD. There is a possibility that in our patients the longstanding clinical course of CRF and maintenance HD resulted in more advanced vascular damage. We therefore speculate that the diffuse systemic vascular damage seen in CRF could explain the increased S-ACE activity seen in these patients.
There was no significant relationship between changes in blood pressure and in levels of enzyme activity. Further studies are necessary to clarify the role of S-ACE activity in the regulation of blood pressure in patients with CRF.
